Platelet Activation in Unstable Coronary Disease

New England Journal of Medicine

Volumn 315, Issue 16, 1986, Pages 983-989

  Fitzgerald, Desmond J ^a   Roy, Louis ^a   Catella, Francesca ^a   Fitzgerald, Garret A ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 2,3 DINORTHROMBOXANE B2; CREATINE KINASE; PROSTACYCLIN; THROMBOXANE; THROMBOXANE A2;

ANGINA PECTORIS; BLOOD AND HEMOPOIETIC SYSTEM; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; DIAGNOSIS; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG MONITORING; DRUG URINE LEVEL; ETIOLOGY; HEART; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; URINARY TRACT;

EID: 0022457212     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198610163151602     Document Type: Article

References (50)

1. Vetrovec GW, Leinbach RC, Gold HK, Cowley MJ. Intracoronary thrombolysis in syndromes of unstable ischemia: angiographic and clinical results. Am Heart J 1982; 104: 946–52.
2. Mandelkorn JB, Wolf NM, Singh S, et al. Intracoronary thrombus in nontransmural myocardial infarction and in unstable angina pectoris. Am J Cardiol 1983; 52: 1–6.
3. Gotoh K, Katoh O, Fukui S, Hamano Y, Minamino T. Angiographic visualization of coronary thrombus during anginal attack in unstable angina. Circulation 1985; 72: Suppl III: III–112. abstract.
4. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913–9.
5. DeWood MA, Spores J, Notske MD, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897–902.
6. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699–708.
7. Davies MJ, Thomas achéal, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 418–27.
8. 2: biosynthesis and effects on platelets. Adv Prostaglandin Thromboxane Leukotriene Res 1982; 10: 15–58.
9. 2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest 1986; 77: 496–502.
10. Ashton JH, Ogletree ML, Taylor AL, et al. A thromboxane receptor antagonist, SQ 29,548, abolishes or attenuates cyclic flow variations in severely narrowed canine coronary arteries. Circulation 1985; 72: Suppl III: III–69. abstract.
11. Reilly IAG, Doran JB, Smith B, FitzGerald GA. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 1986; 73: 1300–9.
12. Reilly IAG, Roy L, FitzGerald GA. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J 1986; 292: 1037–9.
13. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983; 309: 396–403.
14. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–75.
15. 2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. N Engl J Med 1981; 304: 998–1003.
16. Lewy RI, Smith JB, Silver JB, Saia J, Walinsky P, Wiener L. Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. Prostaglandins Med 1979; 2: 243–8.
17. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685–91.
18. 2 production in patients with unstable angina. Am Heart J 1985; 109: 732–8.
19. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174–7.
20. Lawson JA, Brash AR, Doran J, FitzGerald GA. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography–negative-ion chemical ionization mass spectrometry. Anal Biochem 1985; 150: 463–70.
21. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590–4.
22. Lawson JA, Patrono C, Ciabottoni G, FitzGerald GA. Long lived enzymatic metabolites of thromboxane B2 in the human circulation. Anal Biochem 1986; 155: 198–205.
23. Westlund P, Kumlin M, Nordenstrom H, Granstrom E. Circulating and urinary thromboxane B2 metabolites in the rabbit: 11-dehydro-thromboxane B2 as a parameter of thromboxane production. Prostaglandins 1986; 31: 413–44.
24. 2 biosynthesis in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861–5.
25. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897–913.
26. FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation in normal man. J Clin Invest 1981; 68: 1272–6.
27. Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956:184.
28. Mogensen F, Knudsen JB, Rasmussen V, Kjøller E, Gormsen J. Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test. Thromb Res 1985; 37: 259–66.
29. 2. Circulation 1985; 72: 1208–18.
30. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous synthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676–88.
31. Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986; 314: 1214–9.
32. 2/PGH2 mechanisms are both important in mediating cyclic flow variations in severely narrowed canine coronary arteries. Clin Res 1986; 34: 707A. abstract.
33. Henrikkson P, Wennmalm A, Edhag O, Vesterquist O, Green K. In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986; 55: 543–8.
34. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065–8.
35. Schweer H, Kammer J, Seyberth HW. Simultaneous determination of prostanoids in plasma by gas chromatography–negative-ion chemical-ionization mass spectrometry. J Chromatogr 1985; 338: 273–80.
36. Nichols AB, Owen J, Grossman BA, Marcella JJ, Fleisher LN, Lee MML. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. Circulation 1984; 70: 843–50.
37. Bugiardini R, Chierchia S, Crea F, et al. Evaluation of the effects of catheter sampling for the study of platelet behavior in the pulmonary and coronary circulation. Am Heart J 1984; 108: 255–60.
38. Sobel M, Salzman EW, Davies GC, et al. Circulating platelet products in unstable angina pectoris. Circulation 1981; 63: 300–6.
39. Kaplan K, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199–202.
40. Blair IA, Barrow SE, Waddell KA, Lewis PJ, Dollery CT. Prostacyclin is not a circulating hormone in man. Prostaglandins 1982; 23: 579–89.
41. Roy L, Knapp H, Robertson RM, FitzGerald GA. Endogenous biosynthesis of prostacyclin during catheterization and angiography in man. Circulation 1985; 71: 434–9.
42. Fitzgerald DJ, Fragetta J, FitzGerald GA. A chronic canine model of coronary thrombosis: minimization of artifactual increases in prostacyclin and thromboxane synthesis in vivo. Clin Res 1986; 34: 169A. abstract.
43. Patrignani P, Filabozzi P, Patrono C. Selective, cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72.
44. Lewis HD Jr, Davis JW, Archibald DG. Aspirin and the risk of myocardial infarction. N Engl J Med 1984; 310: 122–3.
45. Weksler BB, Tack-Goldman K, Subramanian VA, Gay WA Jr. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation 1985; 71: 332–40.
46. Hutton I, Tweddel achéal, Rankin achéal, Walker ID, Davidson JF. Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease. Br J Clin Pharmacol 1983; 15: Suppl 1: 79S–82S.
47. Thaulow E, Dale J, Myhre E. Effect of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease. Am J Cardiol 1984; 53: 1255–8.
48. Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood (in press).
49. FitzGerald GA, Reilly IAG, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985; 72: 1194–210.
50. Fitzgerald DJ, Fragetta J, Fenelon L, FitzGerald GA. Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis. Adv Prostaglandin Thromboxane Leukotriene Res (in press).